Posts by: Magdalena Kegel

Magdalena Kegel

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

January 23, 2018January 23, 2018

Keytruda Slows Liver Cancer Progression in Phase 2 Trial

News

A study of Keytruda (pembrolizumab) in patients with a difficult-to-treat type of liver cancer suggests that the treatment may extend the time before their disease progresses. Data presented at the ... Read more

January 22, 2018

Rare Melanoma Responds Well to Immunotherapy Despite Thoughts It Wouldn’t, Study Reports

News

A rare type of malignant melanoma is treatable with immunotherapies, according to a new study — overturning previous beliefs that the cancer, called desmoplastic melanoma, is not treatable with such medications. ... Read more

January 3, 2018

Opdivo Approved to Prevent Recurrence in Advanced Melanoma Patients

News

The U.S. Food and Drug Administration (FDA) has agreed that Opdivo (nivolumab) can be used as an adjuvant treatment of certain melanoma patients, to prevent their cancer from returning. The ... Read more

December 4, 2017December 4, 2017

Cerenis May Develop HDL Cholesterol as Tumor Visualization Tool for Targeted Cancer Therapy

News

Cerenis Therapeutics has recruited its first patients into a trial to test whether HDL particles — more commonly known as good cholesterol — can be used to visualize tumors. If proven ... Read more

November 29, 2017November 29, 2017

Tecentriq Add-on Improved Outcomes in Untreated Advanced Lung Cancer Patients

News

Adding Tecentriq (atezolizumab) to a treatment of Avastin (bevacizumab) and chemotherapy significantly prolonged the time to disease progression or death in people with previously untreated advanced non-squamous non-small cell lung ... Read more

October 16, 2017

Large-scale Collaborative Effort Aims to Increase Understanding of Cancer Therapy Combinations

News

In an unprecedented collaborative effort, Stand Up To Cancer (SU2C) has launched 10 clinical trials through its therapy development initiative SU2C Catalyst — projects that will involve researchers from more than ... Read more

October 12, 2017October 12, 2017

Imlygic-Yervoy Combo Twice as Effective as Yervoy in Fighting Melanoma, Study Finds

News

Amgen’s virus therapy against metastatic malignant melanoma, Imlygic, appears to boost the effects of Yervoy (ipilimumab), according to the results of a Phase 2 clinical trial published in the Journal ... Read more

October 2, 2017

Researchers Develop Guidelines for Management of CAR T-cell Triggered Toxicities

News

Researchers have developed guidelines for handling the potentially fatal side effects of CAR T-cell therapy, which along with its unprecedented efficacy in treating certain cancers, comes with a high risk ... Read more

September 27, 2017September 27, 2017

Keytruda Approved as First-Line Lung Cancer Treatment in Canada

News

Canadian patients with metastatic non-small cell lung cancer (NSCLC) can now receive Merck‘s Keytruda (pembrolizumab) as their first treatment following a recent approval by health authorities. The approval covers patients who have ... Read more

September 22, 2017September 22, 2017

European Commission Approves Bavencio as First Immunotherapy for Adult Metastatic Merkel Cell Carcinoma

News

The European Commission (EC) has granted Bavencio (avelumab) marketing approval as the first immunotherapy to treat the aggressive skin cancer metastatic Merkel cell carcinoma in adults. The decision will allow an ... Read more